Hyperhomocysteinemia, hyperfibrinogenemia, and lipoprotein (a) excess in maintenance dialysis patients: A matched case-control study

被引:106
作者
Bostom, AG
Shemin, D
Lapane, KL
Sutherland, P
Nadeau, MR
Wilson, PWF
Yoburn, D
Bausserman, L
Tofler, G
Jacques, PF
Selhub, J
Rosenberg, IH
机构
[1] RHODE ISL HOSP, DIV RENAL DIS, PROVIDENCE, RI 02902 USA
[2] MEM HOSP RHODE ISL, DEPT HLTH EDUC, PAWTUCKET, RI USA
[3] FRAMINGHAM HEART DIS EPIDEMIOL STUDY, FRAMINGHAM, MA USA
[4] MIRIAM HOSP, LIPID METAB LAB, PROVIDENCE, RI USA
[5] DEACONESS HOSP, INST PREVENT CARDIOVASC DIS, BOSTON, MA USA
关键词
fibrinogen; Lp(a); end-stage renal disease; arteriosclerosis;
D O I
10.1016/0021-9150(96)05865-0
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Maintenance dialysis patients experience an exceedingly high incidence of arteriosclerotic cardiovascular disease (CVD) events that are poorly predicted by traditional CVD risk factor indices. We evaluated the prevalence of three non-traditional CVD risk factors, i.e. hyperhomocysteinemia, hyperfibrinogenemia, and lipoprotein (a) (Lp(a)) excess, and combined hyperhomocysteinemia, hyperfibrinogenemia, and Lp(a) excess, in maintenance dialysis patients. Fasting total plasma homocysteine (Hey), fibrinogen, Lp(a), glucose, and total and HDL cholesterol levels, and traditional CVD risk factor (i.e. glucose tolerance, smoking, hypertension, dyslipidemia) prevalences were assessed in 71 dialysis patients and 71 age, sex, and race matched Framingham Study controls free of clinical renal disease, with normal serum creatinine (less than or equal to 1.5 mg/dl). Mean plasma Hey (23.7 vs. 9.9 mu M P = 0.0001), fibrinogen (457 vs. 309 mg/dl, P = 0.0001), and Lp(a) (30 vs. 17 mg/dl, P = 0.0070) levels were substantially increased in the dialysis patients. Matched odds ratios (with 95% confidence intervals), dialysis patients/controls, for hyperhomocysteinemia, hyperfibrinogenemia, and Lp(a) excess, alone or combined, were markedly greater in the dialysis patients, with no evidence of confounding by the traditional CVD risk factors: hyperhomocysteinemia, 105.0 (29.9-368.9); hyperfibrinogenemia, 16.6 (6.6-42.0); Lp(a) excess, 3.5 (1.5-8.4); all three combined 35.0 (5.7-199.8). Given in vitro evidence that Hcy, Lp(a), and fibrinogen interact to promote atherothrombosis, combined hyperhomocysteinemia, hyperfibrinogenemia, and Lp(a) excess may contribute to the high incidence of vascular disease sequelae experienced by dialysis patients, which is inadequately explained by traditional CVD risk factors. Controlled, prospective studies of well-characterized maintenance dialysis cohorts are urgently required to substantiate this hypothesis.
引用
收藏
页码:91 / 101
页数:11
相关论文
共 79 条
  • [1] DETERMINATION OF FREE AND TOTAL HOMOCYSTEINE IN HUMAN-PLASMA BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY WITH FLUORESCENCE DETECTION
    ARAKI, A
    SAKO, Y
    [J]. JOURNAL OF CHROMATOGRAPHY-BIOMEDICAL APPLICATIONS, 1987, 422 : 43 - 52
  • [2] SERUM TOTAL HOMOCYSTEINE AND CORONARY HEART-DISEASE
    ARNESEN, E
    REFSUM, H
    BONAA, KH
    UELAND, PM
    FORDE, OH
    NORDREHAUG, JE
    [J]. INTERNATIONAL JOURNAL OF EPIDEMIOLOGY, 1995, 24 (04) : 704 - 709
  • [3] BACHMANN J, 1995, J AM SOC NEPHROL, V6, P121
  • [4] BERGSTROM J, 1995, J AM SOC NEPHROL, V6, P1329
  • [5] BLACK IW, 1992, CLIN CHEM, V38, P353
  • [6] REVERSE FLUX FILTRATION - A NEW MODE OF THERAPY IMPROVING THE EFFICACY OF HEPARIN - INDUCED EXTRACORPOREAL LDL PRECIPITATION IN HYPERLIPIDEMIC HEMODIALYSIS-PATIENTS
    BOSCH, T
    SAMTLEBEN, W
    THIERY, J
    GURLAND, HJ
    SEIDEL, D
    [J]. INTERNATIONAL JOURNAL OF ARTIFICIAL ORGANS, 1993, 16 (02) : 75 - 85
  • [7] NET UPTAKE OF PLASMA HOMOCYSTEINE BY THE RAT-KIDNEY IN-VIVO
    BOSTOM, A
    BROSNAN, JT
    HALL, B
    NADEAU, MR
    SELHUB, J
    [J]. ATHEROSCLEROSIS, 1995, 116 (01) : 59 - 62
  • [8] A PROSPECTIVE INVESTIGATION OF ELEVATED LIPOPROTEIN(A) DETECTED BY ELECTROPHORESIS AND CARDIOVASCULAR-DISEASE IN WOMEN - THE FRAMINGHAM HEART-STUDY
    BOSTOM, AG
    GAGNON, DR
    CUPPLES, LA
    WILSON, PWF
    JENNER, JL
    ORDOVAS, JM
    SCHAEFER, EJ
    CASTELLI, WP
    [J]. CIRCULATION, 1994, 90 (04) : 1688 - 1695
  • [9] Folate status is the major determinant of fasting total plasma homocysteine levels in maintenance dialysis patients
    Bostom, AG
    Shemin, D
    Lapane, KL
    Nadeau, MR
    Sutherland, P
    Chan, J
    Rozen, R
    Yoburn, D
    Jacques, PF
    Selhub, J
    Rosenberg, IH
    [J]. ATHEROSCLEROSIS, 1996, 123 (1-2) : 193 - 202
  • [10] High dose B-vitamin treatment of hyperhomocysteinemia in dialysis patients
    Bostom, AG
    Shemin, D
    Lapane, KL
    Hume, AL
    Yoburn, D
    Nadeau, MR
    Bendich, A
    Selhub, J
    Rosenberg, IH
    [J]. KIDNEY INTERNATIONAL, 1996, 49 (01) : 147 - 152